Contra-indicated in patients with a confirmed diagnosis of gastroparesis; or with hypoglycemia unawareness.
- TRADE NAME: Symlin (Amylin)
- INDICATIONS: Diabetes; adjunct to insulin treatment
- CLASS: Amylinomimetic, Antidiabetic, Protein analog
- HALF-LIFE: 48 minutes
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acarbose, Acetaminophen, Alcohol, Amitriptyline, Anticholinergics, Atropine, Cyclobenzaprine, Fesoterodine, Insulin Aspart, Insulin Degludec, Insulin Glargine, Insulin Glulisine, Miglitol, Oxybutynin, Tiotropium, Trospium
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
